Is SPPI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,841 people get SPPI articles and Market Currents by email alert.

Get email alerts on SPPI »

HEADLINES:

Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th

Business Wire (Thu, 7:00AM)
Spectrum Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 10 Comments
Spectrum Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14 • 1 Comment
4 Obscure Healthcare Stocks To Watch In 2013
Black Coral Research • Mon, May 13
Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th

Business Wire (May 13, 2013)
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th

Business Wire (May 10, 2013)
Spectrum Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013

Business Wire (May 9, 2013)
Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast

Business Wire (May 2, 2013)
Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia

Business Wire (Apr 8, 2013)
Can Spectrum Pharmaceuticals Regain Investor Trust?
C.R. Jackson • Mon, Apr 1 • 34 Comments
The 'Blitz': Looking At Individual Stocks Presenting Value
Brian Nichols • Sun, Mar 31 • 17 Comments
S&P 1500 Most Heavily Shorted Stocks
Bespoke Investment Group • Thu, Mar 28 • 3 Comments
5 Stocks To Watch For Gains This Week
Brian Nichols • Sat, Mar 23 • 34 Comments
Spectrum Pharmaceuticals, Inc. Sued by Shareholders

PR Newswire (Mar 21, 2013)
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer

Business Wire (Mar 18, 2013)
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
Seeking Opportunity: 10 Stocks To Watch Right Now
Brian Nichols • Fri, Mar 15 • 14 Comments

To learn more about Seeking Alpha Pro, click here.

Can Spectrum Pharmaceuticals Regain Investor Trust?
C.R. Jackson • Mon, Apr 1 • 34 Comments
Fusilev Unravels Spectrum's Revenue Growth, Bears Descend On Company
Brian L. Wilson • Thu, Mar 14 • 4 Comments
Spectrum Pharmaceuticals: Here's One Acquisition Rumor That I Wouldn't Mind Chasing
Brian Nichols • Tue, Feb 5 • 23 Comments
2 Biotech Short-Squeeze Candidates For The New Year
EnhydrisPECorp • Mon, Dec 31, 2012 • 9 Comments
Spectrum's Failure To 'Give Back' Continues To Hurt Its Stock
Brian Nichols • Thu, Nov 8, 2012 • 62 Comments
Trading Spectrum Pharmaceuticals - A Closer Look
Brian L. Wilson • Tue, Oct 16, 2012 • 22 Comments
To Fight The Fear, Eventually You Have To Shake Your Shorts
Michael Webb • Tue, Oct 9, 2012 • 32 Comments
Understanding And Trading Spectrum's Recent Declines
Andrew Mather • Thu, Sep 6, 2012 • 36 Comments
Spectrum Pharmaceuticals: Raj Sets The Record Straight And Quiets The Naysayers
Brian Nichols • Sun, Sep 2, 2012 • 81 Comments
The Bear Case: 3 Reasons To Sell Spectrum Pharmaceuticals
Joe Springer • Wed, Aug 22, 2012 • 31 Comments
The Bull Case: 3 Reasons Spectrum Pharmaceuticals Is A Buy
Joe Springer • Wed, Aug 22, 2012 • 5 Comments
Spectrum Pharmaceuticals Falls Hard With No Logical Explanation
Brian Nichols • Thu, Aug 9, 2012 • 105 Comments
Cash Rich, Fast Growing Biotech With Further Upside Ahead
Bret Jensen • Sun, Aug 5, 2012 • 11 Comments
Spectrum Pharmaceuticals: Bears Beware, Fusilev Strength Points To Strong Second Quarter
Smith On Stocks • Sun, Jul 15, 2012 • 23 Comments
Spectrum Proves To Be A Winner, But Short Still Looms
Shlomi Cohen • Wed, Jul 11, 2012 • 11 Comments
Spectrum Pharmaceuticals Q2 Earnings Estimations: Another Blowout Quarter
Nenoview • Mon, Jul 9, 2012 • 9 Comments
Spectrum Pharmaceuticals Reached 10-Year Highs But Has At Least 20% Upside In The Immediate Future
Brian Nichols • Tue, Jul 3, 2012 • 20 Comments
Spectrum's Huge Short Interest: A Dangerous Or Intriguing Play?
VFC's Stock House • Wed, Jun 20, 2012 • 7 Comments
Is Spectrum Pharmaceuticals Poised To Move Higher?
Kapitall • Mon, Jun 18, 2012 • 3 Comments
Spectrum Pharmaceuticals - The Shorts Are Playing Chicken And Are About To Lose
Nenoview • Thu, Jun 7, 2012 • 6 Comments

A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 10 Comments
4 Obscure Healthcare Stocks To Watch In 2013
Black Coral Research • Mon, May 13
The 'Blitz': Looking At Individual Stocks Presenting Value
Brian Nichols • Sun, Mar 31 • 17 Comments
S&P 1500 Most Heavily Shorted Stocks
Bespoke Investment Group • Thu, Mar 28 • 3 Comments
5 Stocks To Watch For Gains This Week
Brian Nichols • Sat, Mar 23 • 34 Comments
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
Seeking Opportunity: 10 Stocks To Watch Right Now
Brian Nichols • Fri, Mar 15 • 14 Comments
S&P 1500's Most Heavily Shorted Stocks
Bespoke Investment Group • Thu, Mar 14 • 7 Comments
A Quick Look At 8 Biotechs Ready To Gain Momentum
Craig Keolanui • Mon, Mar 11 • 10 Comments
Seeking Opportunity: Creating A Plan Of Investment Action
Brian Nichols • Fri, Mar 8 • 22 Comments
S&P 1500 Most Heavily Shorted Stocks
Bespoke Investment Group • Fri, Feb 15 • 15 Comments
Diversifying Your Portfolio: The $50,000 Growth Strategy
Brian Nichols • Sun, Feb 10 • 25 Comments
Post-Tysabri, Will Elan Waste The Windfall?
Stephen Simpson • Fri, Feb 8 • 5 Comments
Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRay
BuySellShort • Tue, Feb 5 • 3 Comments
4 Companies With High Upside And Large Short Interest
Teresa Dawn • Thu, Jan 31 • 6 Comments
Growing Use Of Radiopharmaceuticals For Fighting Cancer Shows Promise
A John Hodge • Mon, Jan 28 • 5 Comments
S&P 1500 Most Heavily Shorted Stocks
Bespoke Investment Group • Fri, Jan 11 • 7 Comments
We Need More Days Like Today
David Brown • Mon, Dec 17, 2012 • 6 Comments
Targeted Radiation Looks To Create And Grow Revenue
The Swiss Trader • Wed, Dec 5, 2012 • 4 Comments

Spectrum Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM
Mon, May 20
Spectrum Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14 • 1 Comment
Spectrum Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Spectrum Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 21 • 3 Comments
Spectrum Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012 • 2 Comments
Spectrum Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012 • 1 Comment

Spectrum Pharmaceuticals to Present Corporate Update at the Deutsche Bank 38th Annual Health Care Conference in Boston on May 30th

Business Wire (Thu, 7:00AM)
Spectrum Pharmaceuticals to Present Corporate Update at the UBS Global Healthcare Conference in New York City on May 20th

Business Wire (May 13, 2013)
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 14th

Business Wire (May 10, 2013)
Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2013

Business Wire (May 9, 2013)
Spectrum Pharmaceuticals Announces First Quarter 2013 Financial Results Teleconference and Webcast

Business Wire (May 2, 2013)
Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia

Business Wire (Apr 8, 2013)
Spectrum Pharmaceuticals, Inc. Sued by Shareholders

PR Newswire (Mar 21, 2013)
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer

Business Wire (Mar 18, 2013)
Spectrum Pharmaceuticals to Present Corporate Update at the 25th Annual ROTH Conference in Laguna Niguel on March 20th

Business Wire (Mar 15, 2013)
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan

Business Wire (Mar 14, 2013)
Market Snapshot: Stocks gain; Dow has longest win streak since 1996

at MarketWatch.com (Mar 13, 2013)
After Hours: Spectrum Pharma, Velti shares tumble after hours

at MarketWatch.com (Mar 12, 2013)
Spectrum Pharmaceuticals Provides Corporate Update

Business Wire (Mar 12, 2013)
Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2012

Business Wire (Feb 21, 2013)
Spectrum Pharmaceuticals to Present Corporate Update at the RBC Capital Markets Healthcare Conference in New York on February 27th

Business Wire (Feb 20, 2013)
Spectrum Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2012 Financial Results Teleconference and Webcast

Business Wire (Feb 12, 2013)
Spectrum Pharmaceuticals to Present Corporate Update at the Leerink Swann 2013 Global Healthcare Conference in New York on February 14th

Business Wire (Feb 7, 2013)
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application

Business Wire (Jan 31, 2013)
Spectrum Pharmaceuticals Announces Presentation of Belinostat Safety Profile from BELIEF Registrational Phase 2 Trial at the Fifth Annual T-Cell Lymphoma Forum

Business Wire (Jan 28, 2013)
Spectrum Pharmaceuticals Announces Extension of FUSILEV® (levoleucovorin) for Injection Patent Until 2022

Business Wire (Jan 17, 2013)

SPPI vs. ETF Alternatives

Company Description

Overview

We are a commercial stage biopharmaceutical company committed to developing and commercializing innovative therapies with a focus primarily in the areas of hematology-oncology and urology. We have a fully developed commercial infrastructure that is responsible for the sales and... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 3:56 PM The 25 most heavily shorted stocks (as a percent of float) in the S&P 1500 as of the end of April are up 6.75% in May, trouncing the S&P's 2.33% gain, according to Bespoke - and this doesn't include Tesla, up 57% with 40% of its float shorted, but not a S&P 1500 member. The top 5 heavily shorted: BTH, QCOR, CSTR, BRLI, SPPI. The rest in another post. 4 Comments
Thursday, May 9, 7:55 AM Spectrum (SPPI): Q1 EPS of -$0.05 beats by $0.11. Revenue of $38.7M beats by $2.28M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 14, 8:31 AM Spectrum (SPPI +2.2%) signs a licensing and supply deal with Ligand (LGND) for the latter's Captisol-enabled melphalan for use in multiple myeloma transplant programs. Spectrum will pay $3M upfront, over $50M in milestones and then royalties. Ligand also raises its guidance and now expects 2013 EPS of $0.47-0.51 vs consensus of $0.36 and revenues of $43-46M vs $43.2M. For Q1, Ligand predicts EPS of $0.10-0.13 vs -$0.01 and revenues of $10-11M vs $8.04M. (PR) Comment! [Healthcare, Earnings]
Wednesday, March 13, 9:10 AM Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move]
Wednesday, March 13, 8:30 AM Spectrum Pharmaceuticals (SPPI) collapses 35% after it yesterday forecast FY 2013 revenues of $160-180M, well below consensus of $297M, due to weak sales of its Fusilev treatment. "Fusilev is Spectrum's biggest and most important drug, so its demise can't be made up elsewhere," writes The Street's Adam Feuerstein. 2 Comments [Healthcare, On the Move]
Tuesday, March 12, 5:48 PM After-hours top gainers, as of 5:15 p.m.: XNPT +11%. DTSI +8%. ARQL +8%. SGMS +7%. EVER +7%.
After-hours top losers: SPPI -35%. VELT -26%. KTOS -16%. MUX -8%. TEU -8%. 3 Comments [On the Move]
Tuesday, March 12, 4:44 PM Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. 14 Comments [Healthcare, Earnings]
Thursday, February 21, 7:20 AM Spectrum Pharmaceuticals (SPPI): Q4 EPS of $0.27 beats by $0.01. Revenue of $70.1M beats by $0.22M. (PR) 9 Comments [Earnings, Breaking News, Healthcare]
Tuesday, January 29, 4:02 PM Spectrum Pharmaceuticals (SPPI +4.6%) finishes the day higher after saying late yesterday that safety findings from its Phase 2 trial of belinostat showed an acceptable profile in patients with relapsed T-cell lymphoma. 5 Comments [Healthcare, On the Move]
Monday, January 28, 2:00 PM Spectrum Pharmaceuticals (SPPI -1.5%) slips after releasing safety findings from its Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase inhibitor. The trial showed the drug had an acceptable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma, including patients who have received a previous allogeneic or autologous stem cell transplant. SPPI says an NDA filing is expected by mid-2013, and an FDA decision in 2014. 3 Comments [Healthcare, On the Move]
Tuesday, January 15, 3:18 PM Shares of Spectrum Pharmaceuticals (SPPI -0.7%) slip after Credit Suisse initiated the shares with a tepid Neutral rating ealier this morning. The firm says its concerned about the impact of increased competition from Leucovorin, which is a generic SPPI's Fusilev. Sales of Fusilev may decrease from 2012 highs and limit near-term stock performance, and Credit Suisse feels it's more prudent to take a wait-and-see approach and look to buy SPPI once there's greater visibility. 6 Comments [Healthcare]
Friday, January 11, 3:17 PM Spectrum Pharmaceuticals (SPPI -2.4%) says it's promoted Joseph Turgeon to chief commercial officer. He will be responsible for global commercial and sales activities and will report to the company's COO, Ken Keller. The company adds that it's completed the strategic strengthening of its sales force in the U.S., adding 60 sales professionals in an effort to ramp up the marketing of its oncology products. Comment! [Healthcare]
Tuesday, December 11, 2012, 7:11 AM Spectrum Pharmaceuticals (SPPI) declares special dividend of $0.15/share quarterly dividend. For shareholders of record Dec. 20. Payable Dec. 28. Ex-div date Dec. 18. (PR) 4 Comments [Dividends]
Monday, October 29, 2012, 8:42 AM Spectrum Pharmaceuticals (SPPI) names Joseph Turgeon as Senior VP of Sales & Commercial Operations as part of the firm's strategy to expedite growth. Turgeon brings plenty of pharma sales experience, including working for over 20 years at Amgen with Spectrum COO Ken Keller. Meanwhile, Chief Commercial Officer Jim Shields is retiring due to health reasons. (PR) 1 Comment [Healthcare]
Monday, September 24, 2012, 10:08 AM Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II trial for their lymphoma drug belinostat. TopoTarget says the primary endpoint has been met, as the tumors in at least 20% of patients shrank. However, Spectrum is far more cautious, describing the results as "preliminary" and saying that the full outcome won't be known until all the data is analyzed. (PR) 2 Comments [Healthcare, On the Move]
Friday, August 31, 2012, 3:05 PM Spectrum Pharmaceuticals (SPPI -1%) disclosed in a regulatory filing that it expects pro forma revenue to be $300M by the end of 2012. Additionally, it said the list price for its metastatic colorectal and bone cancer treatment, Fusilev, was increased once in Q1 and again in Q2 of 2012. 8 Comments [Healthcare]

mitrado
$AMRN & $SPPI trading at the same levels up to the last cent. It's only the 1000th time it happens, in the last year. Coincidence, for sure!
May 2, 10:23 AM
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: $AMRN drops to $6.99... not much longer until $SPPI does exactly the same.
May 2, 1:05 PM
• !Report Abuse
Add a reply...

140 characters

MagicDiligence
Final new stock is Spectrum Pharma $SPPI. Hematology/oncology biotech. Looks like there are lawsuits outstanding here, short ratio 55%.
Mar 25, 6:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

mmaps@yahoo.com
$SPPI pop, hope it'll hold that level for sometime.
Mar 21, 7:23 AM
Reply (1)

• !Report Abuse
View all 1 replies
William LeGro: When they finally came clean about Fusilev, I thought "crooks." Now a class-action. W/current mgmt, I've lost any hope for this company.
Mar 22, 12:12 PM
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$SPPI A.F. Vindicated. As I predicted, Raj (the problem) will leave this year. Spectrum shareholders will profit nicely on sale/rebirth.
Mar 16, 3:37 PM
Reply (5)

• !Report Abuse
View all 5 replies
mitrado: AF predicted the Fusilev Bubble would burst 2 years ago, when Fusilev was selling around $20m per quarter... but that doesn't matter. Right?
Mar 21, 8:45 AM
• !Report Abuse
Michael Webb: It does matter. You're right. I made reference to the point taken, not the when of it.
Mar 21, 4:26 PM
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday, 13 March - $SNWV.OB, $SPPI, $IMSC.PK, $BA - http://bit.ly/cAHZ42
Mar 13, 10:10 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

vireoman
On E call, $SPPI says demand for Fus "very very very stable." "Govt rebates" the issue. 3 wks later, 2013 rev est for Fus is halved. Liars!
Mar 12, 8:45 PM
Reply (2)

• !Report Abuse
View all 2 replies
mitrado: Another investment turns out to be a gamble. I won't sell as I don't need the money atm and I will only double if and when Raj leaves $SPPI.
Mar 13, 4:22 AM
• !Report Abuse
William LeGro: Isn't that kind of lying illegal? Obviously he knew what was happening long before he told anyone, and still he lied. Isn't that SEC stuff?
Mar 13, 2:13 PM
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch ... $AMRN, $ANTB.OB, $SPPI, $WMT, $DLTR, $SKS, $ONVO.PK, $NVO, $LOW, $BBY http://bit.ly/cAHZ42
Feb 25, 7:49 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch ... $AMRN, $ANTB.OB, $SPPI, $WMT, $DLTR, $SKS, $ONVO.PK, $NVO, $LOW, $BBY ... http://bit.ly/cAHZ42
Feb 24, 5:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

mitrado
$SPPI, $AMRN get good news and fall. $GSK gets terrible news, stock goes up. Welcome to the Wall Street Casino. Place your bets... and pray!
Jan 22, 12:31 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Retail Investor
$SPPI $AMRN Spectrum Shareholders discussion group started- Pls join >http://bit.ly/Vtxkxx
Jan 17, 9:45 PM
Reply (5)

• !Report Abuse
View all 5 replies
mitrado: I was confident in this company but now I feel cheated. The CEO hurt the company a lot more than shortsellers by lying to investors...
Mar 22, 11:20 AM
• !Report Abuse
Retail Investor: yes I am embarrassed to say I was duped. I just hope people who perpetrated this fraud are brought to books.
Mar 22, 6:46 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

mitrado
$AMRN & $SPPI trading at the same levels up to the last cent. It's only the 1000th time it happens, in the last year. Coincidence, for sure!
May 2, 10:23 AM
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: $AMRN drops to $6.99... not much longer until $SPPI does exactly the same.
May 2, 1:05 PM
• !Report Abuse
Add a reply...

140 characters

Retail Investor
$SPPI $AMRN Spectrum Shareholders discussion group started- Pls join >http://bit.ly/Vtxkxx
Jan 17, 9:45 PM
Reply (5)

• !Report Abuse
View all 5 replies
mitrado: I was confident in this company but now I feel cheated. The CEO hurt the company a lot more than shortsellers by lying to investors...
Mar 22, 11:20 AM
• !Report Abuse
Retail Investor: yes I am embarrassed to say I was duped. I just hope people who perpetrated this fraud are brought to books.
Mar 22, 6:46 PM
• !Report Abuse
Add a reply...

140 characters

mmaps@yahoo.com
$SPPI pop, hope it'll hold that level for sometime.
Mar 21, 7:23 AM
Reply (1)

• !Report Abuse
View all 1 replies
William LeGro: When they finally came clean about Fusilev, I thought "crooks." Now a class-action. W/current mgmt, I've lost any hope for this company.
Mar 22, 12:12 PM
• !Report Abuse
Add a reply...

140 characters

Brian Nichols
I like what's happening with $SPPI The trend looks to be positive, shorts have been unable to push below $11
Jan 3, 12:23 PM
Reply (4)

• !Report Abuse
View all 4 replies
Nahodny Okoloiduci: actually it was last batch of planned sale, therefore positive impact.. read recent 8k
Jan 4, 1:59 PM
• !Report Abuse
mitrado: Know we understand why he sold so many shares. He was lying about Fusilev's growth. I really hope Raj leaves. I can never trust him again.
Mar 22, 8:44 AM
• !Report Abuse
Add a reply...

140 characters

craig thomas
Given up trying to figure out why SPPI trades the way it does...maybe i'll just check back again in 6 month's time and see where we are!
11/7/12
Reply (3)

• !Report Abuse
View all 3 replies
mitrado: Me too. SPPI P/E is getting too ridiculous. Maybe I should buy Momenta (MNTA) instead, which has seen its earnings decrease a lot!? :-/
11/8/12
• !Report Abuse
mitrado: Now I realize $MNTA, despite posting losses, would've been a better bet than $SPPI. I should've trusted my instinct: bet on losing pharmas.
Mar 22, 8:44 AM
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$SPPI A.F. Vindicated. As I predicted, Raj (the problem) will leave this year. Spectrum shareholders will profit nicely on sale/rebirth.
Mar 16, 3:37 PM
Reply (5)

• !Report Abuse
View all 5 replies
mitrado: AF predicted the Fusilev Bubble would burst 2 years ago, when Fusilev was selling around $20m per quarter... but that doesn't matter. Right?
Mar 21, 8:45 AM
• !Report Abuse
Michael Webb: It does matter. You're right. I made reference to the point taken, not the when of it.
Mar 21, 4:26 PM
• !Report Abuse
Add a reply...

140 characters

vireoman
On E call, $SPPI says demand for Fus "very very very stable." "Govt rebates" the issue. 3 wks later, 2013 rev est for Fus is halved. Liars!
Mar 12, 8:45 PM
Reply (2)

• !Report Abuse
View all 2 replies
mitrado: Another investment turns out to be a gamble. I won't sell as I don't need the money atm and I will only double if and when Raj leaves $SPPI.
Mar 13, 4:22 AM
• !Report Abuse
William LeGro: Isn't that kind of lying illegal? Obviously he knew what was happening long before he told anyone, and still he lied. Isn't that SEC stuff?
Mar 13, 2:13 PM
• !Report Abuse
Add a reply...

140 characters

FortSumter
$SPPI Been long this stock for almost a year. Heavy manipulated but cheap in terms of valuation. Up 10% in last week. Sold May $13.85 -->
Jan 10, 2:32 PM
Reply (1)

• !Report Abuse
View all 1 replies
FortSumter: covered calls for $1.30 for the inevitable pullback. If not glad to be rid of. Come one Dam F, take'er down.
Jan 10, 2:33 PM
• !Report Abuse
Add a reply...

140 characters

mitrado
$SPPI The tide is turning! Insider buying beginning! Fiscal cliff or not, $SPPI will go up! -D
12/21/12
Reply (3)

• !Report Abuse
View all 3 replies
FortSumter: Love your enthusiasm. But waiting for usual AF or Citron rug pull.
12/22/12
• !Report Abuse
yazan2005: Long SPPI : )
12/22/12
• !Report Abuse
Add a reply...

140 characters

mitrado
$SPPI Adam Feuerstein trolling again: http://bit.ly/Ze3Tm0 | Why does AF keep on lying & misleading investors? http://bit.ly/zcz1QE
12/12/12
Reply (1)

• !Report Abuse
View all 1 replies
Nahodny Okoloiduci: Mr.Fraudenstein Has Unhealthy Obsession With Spectrum Pharmaceuticals
12/12/12
• !Report Abuse
Add a reply...

140 characters

mitrado
Yesterday SPPI tanked. Today AMRN will do the same! If stocks of good companies keep falling. should we invest in losing companies only?
11/8/12
Reply (2)

• !Report Abuse
View all 2 replies
barcaboyvn: Luckily it did not!
11/9/12
• !Report Abuse
mitrado: Well, it crashed a month later... I knew it was on the making. Crooks like Adam Feuerstein should all be put in jail for a very long time.
12/7/12
• !Report Abuse
Add a reply...

140 characters

Michael Webb
$SPPI Look at you Spectrum! Up 8% in the last 13 days.
11/29/12
Reply (1)

• !Report Abuse
View all 1 replies
yazan2005: LONG SPPI : )
11/29/12
• !Report Abuse
Add a reply...

140 characters

Cabeza Howe
Sudden huge block trade on $SPPI, signaling interim bottom and/or good news?
11/13/12
Reply (20)

• !Report Abuse
View all 20 replies
smokeyRose: I Tread the Pharma battle field like it is Mined with a bunch of IED's these Days!
11/15/12
• !Report Abuse
Cabeza Howe: Absolutely agree. Sizing is critical. Never get overexcited. But this is also a time of opportunities thanks to the politicians.
11/15/12
• !Report Abuse
Add a reply...

140 characters

mitrado
After a year watching AMRN, SPPI and Adam Feuershitty's articles, I'm 100% sure both stocks are being manipulated by the same group of cons.
11/12/12
Reply (15)

• !Report Abuse
View all 15 replies
mitrado: Maybe not, look at who's also buying SPPI today: http://bit.ly/ZDBi7r
11/13/12
• !Report Abuse
LEIGHDIST: doesn't mean anything it looks like exercising they rights, regardless good luck i hope it pops for you
11/13/12
• !Report Abuse
Add a reply...

140 characters

mitrado
If there's a seller for every buyer... who the heck is selling SPPI today? And why?
11/7/12
Reply (4)

• !Report Abuse
View all 4 replies
mitrado: 2007-2011 (in $M) Annual Revenue: 28.73 | 38.02 | 74.11 | 192.96 ... Net Income: -14.20 | -19.05 | -48.84 | 48.52 --> P/E Ridiculously low.
11/8/12
• !Report Abuse
mitrado: A P/E under 20 for SPPI makes no sense. I really hope the shorts lose a whole lot of money, cause its only what they deserve.
11/8/12
• !Report Abuse
Add a reply...

140 characters

SPPI Spectrum Pharmaceuticals, Inc.

SPPI

Spectrum Pharmaceuticals, Inc.